Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Helix BioPharma Corp.
HBPCurrent price
0.67 CAD
+0.03 CAD (+4.69%)
Last closed
0.73 CAD
Company
www.helixbiopharma.com
ISIN
CA4229101098
Sector
Healthcare
Industry
Biotechnology
Exchange
Toronto Exchange
Capitalization
36 945 728 CAD
Yield for 12 month
+185.11 %
1Y
3Y
5Y
10Y
15Y
HBP
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada. Address: 1055 West Georgia Street, Vancouver, BC, Canada, V6E 3P3
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
3.5 CADP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-13 064 CAD
Current Quarter
–
Last Quarter
-3 015 CAD
Key Figures HBP
1 year
3 years
5 years
10 years
EBITDA
-9 270 064 CAD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-458.65 %
PEG Ratio
–
Return On Equity TTM
-2220.62 %
Wall Street Target Price
3.5 CAD
Revenue TTM
–
Book Value
-0.002 CAD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.06 CAD
Diluted Eps TTM
-1.06 CAD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics HBP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History HBP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:5
Payout Ratio
–
Last Split Date
16.08.2024
Dividend Date
–
Stock Valuation HBP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-6.3589
Price Book MRQ
77.464
Financials HBP
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators HBP
For 52 weeks
0.5 CAD
1.36 CAD
50 Day MA
1.13 CAD
Shares Short Prior Month
2 334
200 Day MA
1.08 CAD
Short Ratio
0.3
Shares Short
2 081
Short Percent
–
BeatStart